Chemo Combo Racks Up Positive Early-Phase Data for Urothelial Cancer

Seagen and Astellas Pharma are touting positive topline data from an early study of Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda as a treatment for patients with unresectable locally advanced or metastatic urothelial cancer who can’t receive cisplatin treatment.
Source: Drug Industry Daily